GILEAD SCIENCES, INC. Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net
GILEAD SCIENCES, INC. (GILD) reported Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net of $0 for the 12-month period ending 2019-12-31, per its 10-K filed 2020-02-25.
Discontinued › Income Statement › Other Income
us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet · last filed 2020-02-25
- GILEAD SCIENCES, INC. derivative instruments, gain (loss) recognized in income, ineffective portion and amount excluded from effectiveness testing, net for the quarter ending 2018-12-31 was $0.00, a 100.00% decline year-over-year.
- GILEAD SCIENCES, INC. derivative instruments, gain (loss) recognized in income, ineffective portion and amount excluded from effectiveness testing, net for the quarter ending 2018-09-30 was $0.00, a 100.00% decline year-over-year.
- GILEAD SCIENCES, INC. derivative instruments, gain (loss) recognized in income, ineffective portion and amount excluded from effectiveness testing, net for the quarter ending 2018-06-30 was $0.00, a 100.00% decline year-over-year.
- GILEAD SCIENCES, INC. derivative instruments, gain (loss) recognized in income, ineffective portion and amount excluded from effectiveness testing, net for the quarter ending 2018-03-31 was $0.00, a 100.00% decline year-over-year.
- GILEAD SCIENCES, INC. derivative instruments, gain (loss) recognized in income, ineffective portion and amount excluded from effectiveness testing, net for fiscal 2019 was $0.00.
- GILEAD SCIENCES, INC. derivative instruments, gain (loss) recognized in income, ineffective portion and amount excluded from effectiveness testing, net for fiscal 2018 was $0.00, a 100.00% decline from fiscal 2017.
- GILEAD SCIENCES, INC. derivative instruments, gain (loss) recognized in income, ineffective portion and amount excluded from effectiveness testing, net for fiscal 2017 was $41.00M.
- GILEAD SCIENCES, INC. derivative instruments, gain (loss) recognized in income, ineffective portion and amount excluded from effectiveness testing, net for fiscal 2016 was -$32.00M, a 346.15% decline from fiscal 2015.
| Period end | Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net 3 month | Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net 3 month as first filed | Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net 6 month | Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net 6 month as first filed | Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net 9 month | Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net 9 month as first filed | Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net 12 month | Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2019-12-31 | $0.00 10-K · filed 2020-02-25 | |||||||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $0.00 derived: sum of 2 quarters · filed 2020-02-25 | $0.00 derived: sum of 3 quarters · filed 2020-02-25 | $0.00 10-K · filed 2020-02-25 | ||||
| 2018-09-30 | $0.00 10-Q · filed 2018-11-06 | $0.00 derived: sum of 2 quarters · filed 2018-11-06 | $0.00 10-Q · filed 2018-11-06 | $9.00M derived: sum of 4 quarters · filed 2020-02-25 | ||||
| 2018-06-30 | $0.00 10-Q · filed 2018-08-06 | $0.00 10-Q · filed 2018-08-06 | $9.00M derived: sum of 3 quarters · filed 2020-02-25 | $19.00M derived: sum of 4 quarters · filed 2020-02-25 | ||||
| 2018-03-31 | $0.00 10-Q · filed 2018-05-09 | $9.00M derived: sum of 2 quarters · filed 2020-02-25 | $19.00M derived: sum of 3 quarters · filed 2020-02-25 | $28.00M derived: sum of 4 quarters · filed 2020-02-25 | ||||
| 2017-12-31 | $9.00M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $19.00M derived: sum of 2 quarters · filed 2020-02-25 | $28.00M derived: sum of 3 quarters · filed 2020-02-25 | $41.00M 10-K · filed 2020-02-25 | ||||
| 2017-09-30 | $10.00M 10-Q · filed 2018-11-06 | $19.00M derived: sum of 2 quarters · filed 2018-11-06 | $32.00M 10-Q · filed 2018-11-06 | -$38.00M derived: sum of 4 quarters · filed 2019-02-26 | ||||
| 2017-06-30 | $9.00M 10-Q · filed 2017-08-07 | $22.00M 10-Q · filed 2017-08-07 | -$48.00M derived: sum of 3 quarters · filed 2019-02-26 | -$37.00M derived: sum of 4 quarters · filed 2019-02-26 | ||||
| 2017-03-31 | $13.00M 10-Q · filed 2018-05-09 | -$57.00M derived: sum of 2 quarters · filed 2019-02-26 | -$46.00M derived: sum of 3 quarters · filed 2019-02-26 | -$33.00M derived: sum of 4 quarters · filed 2019-02-26 | ||||
| 2016-12-31 | -$70.00M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | -$59.00M derived: sum of 2 quarters · filed 2019-02-26 | -$46.00M derived: sum of 3 quarters · filed 2019-02-26 | -$32.00M 10-K · filed 2019-02-26 | ||||
| 2016-09-30 | $11.00M 10-Q · filed 2017-11-07 | $24.00M derived: sum of 2 quarters · filed 2017-11-07 | $38.00M 10-Q · filed 2017-11-07 | $40.00M derived: sum of 4 quarters · filed 2017-11-07 | ||||
| 2016-06-30 | $13.00M 10-Q · filed 2017-08-07 | $27.00M 10-Q · filed 2017-08-07 | $29.00M derived: sum of 3 quarters · filed 2017-08-07 | $33.00M derived: sum of 4 quarters · filed 2017-08-07 | ||||
| 2016-03-31 | $14.00M 10-Q · filed 2017-05-10 | $16.00M derived: sum of 2 quarters · filed 2017-05-10 | $20.00M derived: sum of 3 quarters · filed 2017-05-10 | $26.00M derived: sum of 4 quarters · filed 2017-05-10 | ||||
| 2015-12-31 | $2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-24 | $6.00M derived: sum of 2 quarters · filed 2016-11-07 | $12.00M derived: sum of 3 quarters · filed 2016-11-07 | $13.00M 10-K · filed 2016-02-24 | ||||
| 2015-09-30 | $4.00M 10-Q · filed 2016-11-07 | $10.00M derived: sum of 2 quarters · filed 2016-11-07 | $11.00M 10-Q · filed 2016-11-07 | $11.00M derived: sum of 4 quarters · filed 2016-11-07 | ||||
| 2015-06-30 | $6.00M 10-Q · filed 2016-08-05 | $7.00M 10-Q · filed 2016-08-05 | $7.00M derived: sum of 3 quarters · filed 2016-08-05 | $4.00M derived: sum of 4 quarters · filed 2016-08-05 | ||||
| 2015-03-31 | $1.00M 10-Q · filed 2016-05-06 | $1.00M derived: sum of 2 quarters · filed 2016-05-06 | -$2.00M derived: sum of 3 quarters · filed 2016-05-06 | -$6.00M derived: sum of 4 quarters · filed 2016-05-06 | ||||
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-24 | -$3.00M derived: sum of 2 quarters · filed 2016-02-24 | -$7.00M derived: sum of 3 quarters · filed 2016-02-24 | -$7.00M 10-K · filed 2016-02-24 | ||||
| 2014-09-30 | -$3.00M 10-Q · filed 2015-11-04 | -$2.63M 10-Q · filed 2014-11-05 | -$7.00M derived: sum of 2 quarters · filed 2015-11-04 | -$7.00M 10-Q · filed 2015-11-04 | -$6.53M 10-Q · filed 2014-11-05 | -$5.88M derived: sum of 4 quarters · filed 2016-02-24 | ||
| 2014-06-30 | -$4.00M 10-Q · filed 2015-08-05 | -$3.98M 10-Q · filed 2014-08-04 | -$4.00M 10-Q · filed 2015-08-05 | -$3.90M 10-Q · filed 2014-08-04 | -$2.88M derived: sum of 3 quarters · filed 2016-02-24 | -$1.78M derived: sum of 4 quarters · filed 2016-02-24 | ||
| 2014-03-31 | $0.00 10-Q · filed 2015-05-08 | $84.00K 10-Q · filed 2014-05-07 | $1.12M derived: sum of 2 quarters · filed 2016-02-24 | $2.22M derived: sum of 3 quarters · filed 2016-02-24 | $4.13M derived: sum of 4 quarters · filed 2016-02-24 | |||
| 2013-12-31 | $1.12M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-24 | $2.22M derived: sum of 2 quarters · filed 2016-02-24 | $4.13M derived: sum of 3 quarters · filed 2016-02-24 | $2.00M 10-K · filed 2016-02-24 | $1.65M 10-K · filed 2014-02-25 | |||
| 2013-09-30 | $1.10M 10-Q · filed 2014-11-05 | $3.01M derived: sum of 2 quarters · filed 2014-11-05 | $881.00K 10-Q · filed 2014-11-05 | $1.32M derived: sum of 4 quarters · filed 2015-02-25 | ||||
| 2013-06-30 | $1.91M 10-Q · filed 2014-08-04 | -$224.00K 10-Q · filed 2014-08-04 | $220.00K derived: sum of 3 quarters · filed 2015-02-25 | -$1.47M derived: sum of 4 quarters · filed 2015-02-25 | ||||
| 2013-03-31 | -$2.13M 10-Q · filed 2014-05-07 | -$1.69M derived: sum of 2 quarters · filed 2015-02-25 | -$3.38M derived: sum of 3 quarters · filed 2015-02-25 | -$6.92M derived: sum of 4 quarters · filed 2015-02-25 | ||||
| 2012-12-31 | $444.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-25 | -$1.24M derived: sum of 2 quarters · filed 2015-02-25 | -$4.79M derived: sum of 3 quarters · filed 2015-02-25 | -$8.00M 10-K · filed 2015-02-25 | -$8.44M 10-K · filed 2013-02-27 | |||
| 2012-09-30 | -$1.69M 10-Q · filed 2013-10-31 | $1.69M 10-Q · filed 2012-11-06 | -$5.23M derived: sum of 2 quarters · filed 2013-10-31 | -$8.44M 10-Q · filed 2013-10-31 | $8.44M 10-Q · filed 2012-11-06 | -$36.51M derived: sum of 4 quarters · filed 2014-02-25 | ||
| 2012-06-30 | -$3.54M 10-Q · filed 2013-08-01 | $3.54M 10-Q · filed 2012-08-01 | -$6.76M 10-Q · filed 2013-08-01 | $6.76M 10-Q · filed 2012-08-01 | -$34.82M derived: sum of 3 quarters · filed 2014-02-25 | -$27.06M derived: sum of 4 quarters · filed 2014-02-25 | ||
| 2012-03-31 | -$3.21M 10-Q · filed 2013-05-08 | $3.21M 10-Q · filed 2012-05-04 | -$31.27M derived: sum of 2 quarters · filed 2014-02-25 | -$23.52M derived: sum of 3 quarters · filed 2014-02-25 | -$19.45M derived: sum of 4 quarters · filed 2014-02-25 | |||
| 2011-12-31 | -$28.06M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-25 | -$20.30M derived: sum of 2 quarters · filed 2014-02-25 | -$16.24M derived: sum of 3 quarters · filed 2014-02-25 | -$17.24M 10-K · filed 2014-02-25 | ||||
| 2011-09-30 | $7.76M 10-Q · filed 2012-11-06 | -$7.76M 10-Q · filed 2011-11-04 | $11.82M derived: sum of 2 quarters · filed 2012-11-06 | $10.82M 10-Q · filed 2012-11-06 | -$10.82M 10-Q · filed 2011-11-04 | $8.22M derived: sum of 4 quarters · filed 2013-02-27 | ||
| 2011-06-30 | $4.06M 10-Q · filed 2012-08-01 | -$4.06M 10-Q · filed 2011-08-05 | $3.07M 10-Q · filed 2012-08-01 | -$3.07M 10-Q · filed 2011-08-05 | $460.00K derived: sum of 3 quarters · filed 2013-02-27 | $5.62M derived: sum of 4 quarters · filed 2013-02-27 | ||
| 2011-03-31 | -$995.00K 10-Q · filed 2012-05-04 | $995.00K 10-Q · filed 2011-05-09 | -$3.60M derived: sum of 2 quarters · filed 2013-02-27 | $1.56M derived: sum of 3 quarters · filed 2013-02-27 | -$335.00K derived: sum of 4 quarters · filed 2013-02-27 | |||
| 2010-12-31 | -$2.61M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-27 | $2.55M derived: sum of 2 quarters · filed 2013-02-27 | $660.00K derived: sum of 3 quarters · filed 2013-02-27 | $887.00K 10-K · filed 2013-02-27 | ||||
| 2010-09-30 | $5.16M 10-Q · filed 2011-11-04 | $3.27M derived: sum of 2 quarters · filed 2011-11-04 | $3.49M 10-Q · filed 2011-11-04 | $3.73M derived: sum of 4 quarters · filed 2011-11-04 | ||||
| 2010-06-30 | -$1.89M 10-Q · filed 2011-08-05 | -$1.67M 10-Q · filed 2011-08-05 | -$1.43M derived: sum of 3 quarters · filed 2011-08-05 | -$626.00K derived: sum of 4 quarters · filed 2011-08-05 | ||||
| 2010-03-31 | $227.00K 10-Q · filed 2011-05-09 | $460.00K derived: sum of 2 quarters · filed 2011-05-09 | $1.27M derived: sum of 3 quarters · filed 2011-05-09 | $1.85M derived: sum of 4 quarters · filed 2011-05-09 | ||||
| 2009-12-31 | $233.00K derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-28 | $1.04M derived: sum of 2 quarters · filed 2011-02-28 | $1.63M derived: sum of 3 quarters · filed 2011-02-28 | -$14.49M 10-K · filed 2011-02-28 | ||||
| 2009-09-30 | $806.00K 10-Q · filed 2010-11-08 | $1.40M derived: sum of 2 quarters · filed 2010-11-08 | -$14.73M 10-Q · filed 2010-11-08 | |||||
| 2009-06-30 | $589.00K 10-Q · filed 2010-08-09 | -$15.53M 10-Q · filed 2010-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |